Adaptive Biotechnologies raised its 2026 outlook, forecasting at least 20% revenue growth in its minimal residual disease (MRD) business driven by adoption of its ClonoSeq assay and expanded use across hematologic indications. The company reported strong Q4 and full‑year 2025 revenue gains and expects test volume to climb roughly 30% in 2026 as blood‑based MRD testing penetrates community settings. Adaptive plans to raise average selling prices through payor contract renegotiation and to scale MRD services for registrational trials. Management cited regulatory and clinical momentum behind MRD as a validated endpoint—factors that could translate into durable commercial and clinical trial demand for sequencing‑based diagnostics.